Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT05841654
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Registry
-
NCT05841654
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05841654. Randomized; single masking; primary purpose prevention. Start 2023-06-01 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension
- Acronym
- AZAF
- Condition
- Hypertension
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
Record details
- Record id
cardio:ct-nct05841654- Content hash
6b765f27b93cb291f6b406998e774bf4e135894e76ba8c8ceeba921a1b897d9c